# Sermorelin Benefits Reported in Research — Graded by Evidence

> Sermorelin benefits, separated by how well each is proven: the documented GH/IGF-1 and growth effects, the borrowed tesamorelin claims, and the unproven frontier hopes.

## The gist

If you want the honest list of sermorelin benefits, the trick is to sort them by how strong the evidence is — which is exactly what this page does. Strongest: it reliably raises the body's own growth hormone and IGF-1, and it accelerated growth in deficient children [1][2]. Borrowed: a lot of the "fat loss and sharper thinking" claims actually come from tesamorelin trials, a different (longer-acting) GHRH analog [7]. Unproven-but-interesting: wound healing and even an anti-cancer signal exist only in animals or computer models [8][9].

The point is not to dismiss sermorelin — the proven part is genuinely a drug-grade result. The point is to keep the grades visible so a reader knows which claims have a human trial behind them and which have a mouse, a petri dish, or an algorithm.

## Tier 1 — benefits with human trial evidence

The best-supported sermorelin benefit is restoring a flagging GH/IGF-1 axis. In growth-hormone-deficient children, daily injections roughly doubled first-year height velocity (from ~4.1 to ~7-8 cm/year) without excessive IGF-1 [1] — a real, replicated clinical outcome. In healthy older men, two weeks of twice-daily injections raised 24-hour GH and IGF-1 dose-dependently and brought those markers back toward young-adult levels, without disturbing fasting glucose [2]. The pharmacology confirms the lever is reliable: GH release from doses as low as 0.25 mcg/kg, sustained for about three hours per dose [3]. **Evidence grade: human, including a randomized pediatric trial.**

## Tier 2 — benefits often credited to sermorelin but measured in a different analog

Much of the popular benefits list — body-fat reduction, cognitive sharpening — traces to tesamorelin, not native sermorelin. A randomized, placebo-controlled trial of 152 older adults found that the stabilized GHRH analog tesamorelin (1 mg/day for 20 weeks) produced a favorable cognition effect (P=0.03, executive function P=0.005), raised IGF-1 by 117% within the physiologic range, and cut body fat by 7.4%, with mild adverse events [7]. These are encouraging GHRH-axis results — but assigning them to sermorelin overstates sermorelin's own record. **Evidence grade: human trial, but of a related molecule (tesamorelin), not sermorelin.**

## Tier 3 — frontier benefits that are preclinical or in-silico only

Here is where due diligence earns its keep. GHRH agonist analogs (MR-409, MR-502) drove human skin-cell proliferation and survival through ERK and AKT pathways, and topical MR-409 sped wound closure in animals [8] — promising regenerative biology, but animal and cell-culture data. A GHRH agonist improved a mouse heart-failure model [10], and another study targeted the GHRH receptor for cardiac repair after a heart attack [11]. The cancer headline is the thinnest: an in-silico screen across 1,018 glioma patients flagged sermorelin as a candidate, a computational drug-repurposing prediction, not a clinical trial [9]. **Evidence grade: preclinical (animal/cell) to in-silico — hypothesis-generating, not proof of human benefit.** A 2025 Nature Reviews Endocrinology review frames this whole frontier without overselling it [6].

## What the benefits picture does not include

It does not yet include long-term adult anti-aging benefit or safety; an Annals of Internal Medicine editorial called secretagogue anti-aging use "not yet ready for prime time" [5]. It does not include evidence that the in-silico cancer signal translates to people [9]. And it does not include any human dosing this site would endorse. The benefit worth stating plainly is the proven one: sermorelin reliably and physiologically raises the body's own growth hormone [1][2] — everything past that needs its grade attached. See [Sermorelin research](/research) for the underlying studies and [Sermorelin references](/references) for sources.

---

An engineering-datasheet reading of the sermorelin record — every GHRH(1-29) figure logged to its study and stamped with an evidence grade, the proven pediatric trial kept apart from the borrowed tesamorelin numbers and both apart from the in-silico oncology and preclinical regenerative signals; no clinic behind the spec sheet and nothing here dosed, compounded, prescribed, or sold.